Results 161 to 170 of about 48,655 (322)

Contraceptive Potential of FDA Approved Excipient N,N-Dimethylacetamide

, 2020
Nupur Khera
openalex   +1 more source

Cost Analysis of Clinical Compounding in Saudi Arabia: Excipients and Vehicles of Pediatric Formulations [PDF]

, 2019
Yousef Ahmed Alomi, Malika Alhada, Faiz A Bahadig, Mona Lubbad, Ebtesam Nazal   +4 more
openalex   +1 more source

Selecting surfactants for the maximum inhibition of the activity of the multidrug resistance efflux pump transporter, P-glycoprotein: conceptual development

Journal of Excipients and Food Chemicals, 2010
Amphiphilic excipients, such as surfactants, have been shown to be inhibitors of the multidrug resistance (MDR) efflux pump transporter protein, P glycoprotein (Pgp).
Shireesh Apte
doaj  

Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC

Contact Dermatitis, EarlyView.
ABSTRACT Background Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.
Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie‐L. A. Schuttelaar, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC, Birger Kränke, Alexander Navarini, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Dimitra Koumaki, Maddalena Napolitano, Anna Belloni Fortina, Francesca Larese Filon, Rosella Gallo, Thomas Rustemeyer, Radoslaw Spiewak, Maja Kalac Pandurovic, Tanja Kmecl, Mojca Simončič Godnič, Nada Kecelj, Philippa Cousen, Ella Dendooven, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, María Antonia Pastor Nieto, Francisco Navarro Triviño, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez   +73 more
wiley   +1 more source

Investigation of the effects of excipients on technological properties tablets of pyrola rotundifolia extract

, 2018
N. P. Darzuli, Т. А. Hroshovyi, Kateryna Sokolova, Elena Podpletnyaya   +3 more
openalex   +2 more sources

EXTRACTION AND EVALUATION OF ISAPGHULA SEED POLYMER AS PHARMACEUTICAL EXCIPIENT

, 2014
Praveen Kumar Nagar, Nayyar Parvez, Pramod Kumar Sharma   +2 more
openalex   +2 more sources

Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Introduction Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors. Objectives To develop a feasible and easy‐to‐apply treatment regimen for long‐time disease control of DSAP including prevention of new skin tumors. Patients and Methods 19 patients with DSAP
Berenice M. Lang, Gregor Ojak, Mandy Crummenauer, Joanna Wegner, Caroline Mann, Stephan Grabbe, Petra Staubach   +6 more
wiley   +1 more source

Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions. [PDF]

MAbs
Shelley JC, Chai Q, Wu L, Vafaei S, Shelley MY, Feyfant E, Feng J, Woldeyes MA, Babin V, Jou JD.   +9 more
europepmc   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Navigating the complexity of oral peptide delivery: challenges and strategies to enhance oral bioavailability. [PDF]

Front Drug Deliv
Khalid NU, Rivera-Delgado E, von Erlach T.   +2 more
europepmc   +1 more source